Iams Wealth Management LLC Sells 2,360 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Iams Wealth Management LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,810 shares of the biopharmaceutical company’s stock after selling 2,360 shares during the period. Gilead Sciences accounts for 1.2% of Iams Wealth Management LLC’s portfolio, making the stock its 22nd largest position. Iams Wealth Management LLC’s holdings in Gilead Sciences were worth $2,569,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Asset Dedication LLC increased its position in shares of Gilead Sciences by 43.3% during the fourth quarter. Asset Dedication LLC now owns 6,421 shares of the biopharmaceutical company’s stock valued at $593,000 after acquiring an additional 1,940 shares in the last quarter. Twelve Points Wealth Management LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $611,000. SteelPeak Wealth LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $4,921,000. Mayflower Financial Advisors LLC bought a new stake in Gilead Sciences in the 4th quarter worth approximately $317,000. Finally, BSW Wealth Partners grew its position in Gilead Sciences by 5.9% in the 4th quarter. BSW Wealth Partners now owns 6,048 shares of the biopharmaceutical company’s stock worth $559,000 after purchasing an additional 335 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on GILD shares. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $84.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Truist Financial lifted their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Finally, Barclays lifted their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last ninety days. 0.16% of the stock is owned by company insiders.

Gilead Sciences Stock Up 1.5 %

Shares of NASDAQ GILD opened at $95.28 on Wednesday. The firm’s 50-day moving average price is $92.00 and its 200-day moving average price is $85.44. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $118.74 billion, a price-to-earnings ratio of 1,050.36, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the company earned $2.29 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.